| PE23.03 | Ten years of the AVAC Advocacy Fellows Program: An evaluation | E-poster | Policy and advocacy |
| PE23.02 | Adoption of WHO's HIV retesting policy for HIV-negative women during the breastfeeding period in 10 high HIV-burden African countries | E-poster | Policy and advocacy |
| PE23.01 | Identifying regional disparities in access to HIV and sexual health resources for young men who have sex with men in the United States: The iREACH Study | E-poster | Policy and advocacy |
| PE22.03 | Impact of UGT induction by rifampin and rifabutin on cabotegravir long-acting pharmacokinetics for HIV pre-exposure prophylaxis (PrEP) using population pharmacokinetic modeling and simulation | E-poster | Pharmacology/PK and PD studies |
| PE22.02 | MRI examination of cabotegravir long-acting formulation depot kinetics in healthy adult volunteers | E-poster | Pharmacology/PK and PD studies |
| PE22.01 | Directly Observed Therapy (DOT) can be Implemented Successfully in Research Settings to Evaluate PrEP PK among Pregnant and Postpartum Adolescents and Young Women in Africa | E-poster | Novel vaccine and other prevention approaches |
| PE21.07LB | HIV-1 fusion peptide (FP) conjugate and envelope trimer cocktail immunization elicit diverse FP-directed neutralizing antibodies in non-human primates | E-poster | Novel vaccine and other prevention approaches |
| PE21.05LB | Immunization with HIV-1 fusion peptide carrier conjugate in a cocktail with HIV-envelope trimer elicits potent and cross-clade neutralization activity in guinea pigs | E-poster | Novel vaccine and other prevention approaches |
| PE21.04LB | Advances in the use of a bacterially derived glycoside for inducing oligomannose-targeted neutralizing antibodies to HIV-1 | E-poster | Novel vaccine and other prevention approaches |
| PE21.02 | CD40-targeted vaccine increases magnitude of HIV-Env specific responses | E-poster | Novel vaccine and other prevention approaches |